Hyun-Kyoung Koo1, Dragoş M Vasilescu2, Steven Booth1, Aileen Hsieh2, Orestis L Katsamenis3, Nick Fishbane2, W Mark Elliott2, Miranda Kirby2, Peter Lackie4, Ian Sinclair3, Jane A Warner4, Joel D Cooper5, Harvey O Coxson2, Peter D Paré6, James C Hogg7, Tillie-Louise Hackett8. 1. Centre for Heart Lung Innovation, University of British Columbia, St Paul's Hospital, Vancouver, BC, Canada; Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, Vancouver, BC, Canada. 2. Centre for Heart Lung Innovation, University of British Columbia, St Paul's Hospital, Vancouver, BC, Canada. 3. μ-VIS X-ray Imaging Centre, Faculty of Engineering and the Environment, University of Southampton, Southampton, UK. 4. Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK. 5. Division of Thoracic Surgery, University of Pennsylvania, Philadelphia, PA, USA. 6. Centre for Heart Lung Innovation, University of British Columbia, St Paul's Hospital, Vancouver, BC, Canada; Department of Medicine, University of British Columbia, Vancouver, BC, Canada. 7. Centre for Heart Lung Innovation, University of British Columbia, St Paul's Hospital, Vancouver, BC, Canada; Department of Pathology, University of British Columbia, Vancouver, BC, Canada. 8. Centre for Heart Lung Innovation, University of British Columbia, St Paul's Hospital, Vancouver, BC, Canada; Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, Vancouver, BC, Canada. Electronic address: tillie.hackett@hli.ubc.ca.
Abstract
BACKGROUND: The concept that small conducting airways less than 2 mm in diameter become the major site of airflow obstruction in chronic obstructive pulmonary disease (COPD) is well established in the scientific literature, and the last generation of small conducting airways, terminal bronchioles, are known to be destroyed in patients with very severe COPD. We aimed to determine whether destruction of the terminal and transitional bronchioles (the first generation of respiratory airways) occurs before, or in parallel with, emphysematous tissue destruction. METHODS: In this cross-sectional analysis, we applied a novel multiresolution CT imaging protocol to tissue samples obtained using a systematic uniform sampling method to obtain representative unbiased samples of the whole lung or lobe of smokers with normal lung function (controls) and patients with mild COPD (Global Initiative for Chronic Obstructive Lung Disease [GOLD] stage 1), moderate COPD (GOLD 2), or very severe COPD (GOLD 4). Patients with GOLD 1 or GOLD 2 COPD and smokers with normal lung function had undergone lobectomy and pneumonectomy, and patients with GOLD 4 COPD had undergone lung transplantation. Lung tissue samples were used for stereological assessment of the number and morphology of terminal and transitional bronchioles, airspace size (mean linear intercept), and alveolar surface area. FINDINGS: Of the 34 patients included in this study, ten were controls (smokers with normal lung function), ten patients had GOLD 1 COPD, eight had GOLD 2 COPD, and six had GOLD 4 COPD with centrilobular emphysema. The 34 lung specimens provided 262 lung samples. Compared with control smokers, the number of terminal bronchioles decreased by 40% in patients with GOLD 1 COPD (p=0·014) and 43% in patients with GOLD 2 COPD (p=0·036), the number of transitional bronchioles decreased by 56% in patients with GOLD 1 COPD (p=0·0001) and 59% in patients with GOLD 2 COPD (p=0·0001), and alveolar surface area decreased by 33% in patients with GOLD 1 COPD (p=0·019) and 45% in patients with GOLD 2 COPD (p=0·0021). These pathological changes were found to correlate with lung function decline. We also showed significant loss of terminal and transitional bronchioles in lung samples from patients with GOLD 1 or GOLD 2 COPD that had a normal alveolar surface area. Remaining small airways were found to have thickened walls and narrowed lumens, which become more obstructed with increasing COPD GOLD stage. INTERPRETATION: These data show that small airways disease is a pathological feature in mild and moderate COPD. Importantly, this study emphasises that early intervention for disease modification might be required by patients with mild or moderate COPD. FUNDING: Canadian Institutes of Health Research.
BACKGROUND: The concept that small conducting airways less than 2 mm in diameter become the major site of airflow obstruction in chronic obstructive pulmonary disease (COPD) is well established in the scientific literature, and the last generation of small conducting airways, terminal bronchioles, are known to be destroyed in patients with very severe COPD. We aimed to determine whether destruction of the terminal and transitional bronchioles (the first generation of respiratory airways) occurs before, or in parallel with, emphysematous tissue destruction. METHODS: In this cross-sectional analysis, we applied a novel multiresolution CT imaging protocol to tissue samples obtained using a systematic uniform sampling method to obtain representative unbiased samples of the whole lung or lobe of smokers with normal lung function (controls) and patients with mild COPD (Global Initiative for Chronic Obstructive Lung Disease [GOLD] stage 1), moderate COPD (GOLD 2), or very severe COPD (GOLD 4). Patients with GOLD 1 or GOLD 2 COPD and smokers with normal lung function had undergone lobectomy and pneumonectomy, and patients with GOLD 4 COPD had undergone lung transplantation. Lung tissue samples were used for stereological assessment of the number and morphology of terminal and transitional bronchioles, airspace size (mean linear intercept), and alveolar surface area. FINDINGS: Of the 34 patients included in this study, ten were controls (smokers with normal lung function), ten patients had GOLD 1 COPD, eight had GOLD 2 COPD, and six had GOLD 4 COPD with centrilobular emphysema. The 34 lung specimens provided 262 lung samples. Compared with control smokers, the number of terminal bronchioles decreased by 40% in patients with GOLD 1 COPD (p=0·014) and 43% in patients with GOLD 2 COPD (p=0·036), the number of transitional bronchioles decreased by 56% in patients with GOLD 1 COPD (p=0·0001) and 59% in patients with GOLD 2 COPD (p=0·0001), and alveolar surface area decreased by 33% in patients with GOLD 1 COPD (p=0·019) and 45% in patients with GOLD 2 COPD (p=0·0021). These pathological changes were found to correlate with lung function decline. We also showed significant loss of terminal and transitional bronchioles in lung samples from patients with GOLD 1 or GOLD 2 COPD that had a normal alveolar surface area. Remaining small airways were found to have thickened walls and narrowed lumens, which become more obstructed with increasing COPD GOLD stage. INTERPRETATION: These data show that small airways disease is a pathological feature in mild and moderate COPD. Importantly, this study emphasises that early intervention for disease modification might be required by patients with mild or moderate COPD. FUNDING: Canadian Institutes of Health Research.
Authors: Sandeep Bodduluri; Arie Nakhmani; Joseph M Reinhardt; Carla G Wilson; Merry-Lynn McDonald; Ramaraju Rudraraju; Byron C Jaeger; Nirav R Bhakta; Peter J Castaldi; Frank C Sciurba; Chengcui Zhang; Purushotham V Bangalore; Surya P Bhatt Journal: JCI Insight Date: 2020-07-09
Authors: Wayne Mitzner; Tillie L Hackett; Leila B Mostaco-Guidolin; Jeffrey Loube; Aaron Barlow; Emmanuel T Osei; Dragoș M Vasilescu; Aileen Hsieh; May Fouadi; Christine Young; Alan L Scott Journal: Histochem Cell Biol Date: 2021-01-30 Impact factor: 4.304
Authors: Dragoş M Vasilescu; Fernando J Martinez; Nathaniel Marchetti; Craig J Galbán; Charles Hatt; Catherine A Meldrum; Chandra Dass; Naoya Tanabe; Rishindra M Reddy; Amir Lagstein; Brian D Ross; Wassim W Labaki; Susan Murray; Xia Meng; Jeffrey L Curtis; Tillie L Hackett; Ella A Kazerooni; Gerard J Criner; James C Hogg; MeiLan K Han Journal: Am J Respir Crit Care Med Date: 2019-09-01 Impact factor: 21.405
Authors: Dragoş M Vasilescu; André B Phillion; Daisuke Kinose; Stijn E Verleden; Bart M Vanaudenaerde; Geert M Verleden; Dirk Van Raemdonck; Christopher S Stevenson; Cameron J Hague; MeiLan K Han; Joel D Cooper; Tillie-Louise Hackett; James C Hogg Journal: J Appl Physiol (1985) Date: 2020-04-16
Authors: Stijn E Verleden; Naoya Tanabe; John E McDonough; Dragoş M Vasilescu; Feng Xu; Wim A Wuyts; Davide Piloni; Laurens De Sadeleer; Stijn Willems; Cindy Mai; Jeroen Hostens; Joel D Cooper; Erik K Verbeken; Johny Verschakelen; Craig J Galban; Dirk E Van Raemdonck; Thomas V Colby; Marc Decramer; Geert M Verleden; Naftali Kaminski; Tillie-Louise Hackett; Bart M Vanaudenaerde; James C Hogg Journal: Lancet Respir Med Date: 2020-02-13 Impact factor: 30.700
Authors: Suresh Garudadri; Prescott G Woodruff; MeiLan K Han; Jeffrey L Curtis; R Graham Barr; Eugene R Bleecker; Russell P Bowler; Alejandro Comellas; Christopher B Cooper; Gerard Criner; Mark T Dransfield; Nadia N Hansel; Robert Paine; Jerry A Krishnan; Stephen P Peters; Annette T Hastie; Fernando J Martinez; Wanda K O'Neal; David J Couper; Neil E Alexis; Stephanie A Christenson Journal: Chest Date: 2019-01-23 Impact factor: 9.410
Authors: Sandeep Bodduluri; Abhilash S Kizhakke Puliyakote; Sarah E Gerard; Joseph M Reinhardt; Eric A Hoffman; John D Newell; Hrudaya P Nath; MeiLan K Han; George R Washko; Raúl San José Estépar; Mark T Dransfield; Surya P Bhatt Journal: J Clin Invest Date: 2018-10-29 Impact factor: 14.808